Respir Med 2018 May 19;138S:S7-S13. Epub 2018 Feb 19.
Interstitial Lung Diseases Center of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands; Division of Heart&Lungs, University Medical Center, Utrecht, The Netherlands.
Background: Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of Infliximab, Remicade, is expensive, limiting universal access. Recently, a less expensive biosimilar of infliximab, Inflectra, has become available, but the efficacy and tolerability has not been studied in sarcoidosis. Read More